Drug intelligence / Profile preview

NP-201

Development stage: Phase 3
Lead developer: NIBEC
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Injection

Overview

NP-201 is a peptide therapeutic developed by NIBEC for the treatment of ulcerative colitis and has also been studied in pulmonary fibrosis. It is classified as an anti-inflammatory peptide and is administered via injection. The precise mechanism of action for NP-201 remains undefined or unknown as of the latest clinical updates. Clinical development includes Phase 1b/2a trials in healthy adults and patients with mild-to-moderate active ulcerative colitis, with studies conducted in South Korea and Australia. No serious adverse reactions have been reported to date in clinical trials[1][4][5][7].

Other names: NP-201 AcetateNP201 AcetateNP 201 Acetate

Targets

ITGB5 (Integrin beta-5)

Beyond the preview

Go deeper on NP-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NP-201.

Explore the full profile